NFKB1 and glioblastoma: It has been shown that the NF-κB pathway is activated preferentially in cancer and CSCs of diverse malignancies, including leukemia, glioblastoma, prostate, ovary, breast, pancreatic and colon cancer and its activation is known to induce radio- and chemotherapy resistance [32–38].